519059-08-6

Basic information

• Product Name: 3-cyano-4-fluorobenzoyl chloride
• Synonyms: 3-cyano-4-fluorobenzoyl chloride
• CAS NO: 519059-08-6
• Molecular Weight: 183.569
• Mol File: 519059-08-6.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 3-cyano-4-fluorobenzoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 3-cyano-4-fluorobenzoyl chloride(519059-08-6)
• EPA Substance Registry System: 3-cyano-4-fluorobenzoyl chloride(519059-08-6)

Safety Data

• Hazardous Substances Data: 519059-08-6(Hazardous Substances Data)

Upstream product

• 171050-06-9 3-cyano-4-fluorobenzoic acid 
• 218301-22-5 2-fluoro-5-formylbenzonitrile 

Downstream Products

• 1086626-55-2 2-fluoro-5-(3-(2-isobutoxyphenyl)-3-oxopropanoyl)benzonitrile 
• 1286750-72-8 sodium 3-(6-(5-(4-butoxy-3-cyanophenyl)-1,2,4-oxadiazol-3-yl)-5-methyl-3,4-dihydro-2(1H)-isoquinolinyl)propanoate 
• 1286751-14-1 ethyl 3-[6-{5-[4-(butyloxy)-3-cyanophenyl]-1,2,4-oxadiazol-3-yl}-5-methyl-3,4-dihydro-2(1H)-isoquinolinyl]propanoate 
• 1286751-12-9 2-(butyloxy)-5-[3-(5-methyl-1,2,3,4-tetrahydro-6-isoquinolinyl)-1,2,4-oxadiazol-5-yl]benzonitrile hydrochloride 
• 1286751-11-8 1,1-dimethylethyl 6-{5-[4-(butyloxy)-3-cyanophenyl]-1,2,4-oxadiazol-3-yl}-5-methyl-3,4-dihydro-2(1H)-isoquinolinecarboxylate 
• 1286750-69-3 sodium 3-[6-(5-(3-cyano-4-propoxyphenyl)-1,2,4-oxadiazol-3-yl)-5-methyl-3,4-dihydro-2(1H)-isoquinolinyl]propanoate 
• 1286751-09-4 ethyl 3-(6-(5-(3-cyano-4-propoxyphenyl)-1,2,4-oxadiazol-3-yl)-5-methyl-3,4-dihydro-2(1H)-isoquinolinyl)propanoate 
• 1286751-06-1 5-(3-(5-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)-1,2,4-oxadiazol-5-yl)-2-propoxybenzonitrile hydrochloride 
• 1286751-05-0 1,1-dimethylethyl 6-{5-[3-cyano-4-(propyloxy)phenyl]-1,2,4-oxadiazol-3-yl}-5-methyl-3,4-dihydro-2(1H)-isoquinolinecarboxylate 
• 1286751-03-8 1,1-dimethylethyl 6-[5-(3-cyano-4-fluorophenyl)-1,2,4-oxadiazol-3-yl]-5-methyl-3,4-dihydro-2(1H)-isoquinolinecarboxylate 
• 1258853-31-4 5-{3-[3-(2,3-dihydroxypropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-1,2,4-oxadiazol-5-yl}-2-(3-fluoro-1-azetidinyl)benzonitrile 
• 1258853-20-1 2-(3-fluoro-1-azetidinyl)-5-[3-(3-glycyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1,2,4-oxadiazol-5-yl]benzonitrile 
• 1258852-96-8 5-{3-[3-(2,3-dihydroxypropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-1,2,4-oxadiazol-5-yl}-2-(ethyloxy)benzonitrile 
• 1258852-89-9 5-[3-(3-glycyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1,2,4-oxadi azol-5-yl]-2-(propyloxy)benzonitrile 

Relevant articles and documents

The impact of binding site waters on the activity/selectivity trade-off of Janus kinase 2 (JAK2) inhibitors

Structure based optimization of B39, an indazole-based low micromolar JAK2 virtual screening hit is reported. Analysing the effect of certain modifications on the activity and selectivity of the analogues suggested that these parameters are influenced by

Discovery of a selective S1P1 receptor agonist efficacious at low oral dose and devoid of effects on heart rate

Gilenya (fingolimod, FTY720) was recently approved by the U.S. FDA for the treatment of patients with remitting relapsing multiple sclerosis (RRMS). It is a potent agonist of four of the five sphingosine 1-phosphate (S1P) G-protein-coupled receptors (S1P1 and S1P3-5). It has been postulated that fingolimod's efficacy is due to S1P1 agonism, while its cardiovascular side effects (transient bradycardia and hypertension) are due to S1P3 agonism. We have discovered a series of selective S1P 1 agonists, which includes 3-[6-(5-{3-cyano-4-[(1-methylethyl)oxy] phenyl}-1,2,4-oxadiazol-3-yl)-5-methyl-3,4-dihydro-2(1H)-isoquinolinyl] propanoate, 20, a potent, S1P3-sparing, orally active S1P1 agonist. Compound 20 is as efficacious as fingolimod in a collagen-induced arthritis model and shows excellent pharmacokinetic properties preclinically. Importantly, the selectivity of 20 against S1P3 is responsible for an absence of cardiovascular signal in telemetered rats, even at high dose levels.

S1P1 AGONISTS COMPRISING A BICYCLIC N-CONTAINING RING

The present invention relates to novel compounds of formula (I) having S1P1 agonist activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.